Current Hematologic Malignancy Reports

Scope & Guideline

Empowering Research for Better Patient Outcomes

Introduction

Explore the comprehensive scope of Current Hematologic Malignancy Reports through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Current Hematologic Malignancy Reports in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1558-8211
PublisherCURRENT MEDICINE GROUP
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2006 to 2024
AbbreviationCURR HEMATOL MALIG R / Curr. Hematol. Malig. Rep.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106

Aims and Scopes

The journal 'Current Hematologic Malignancy Reports' aims to provide comprehensive insights into the evolving landscape of hematologic malignancies, encompassing a range of topics from clinical management to novel therapeutic strategies. Its focus is on advancing knowledge and improving patient outcomes through the dissemination of cutting-edge research and expert opinions.
  1. Clinical Management of Hematologic Malignancies:
    The journal covers various aspects of the clinical management of hematologic cancers, including treatment strategies, patient care, and management of side effects associated with therapies.
  2. Innovative Therapeutic Approaches:
    A significant emphasis is placed on novel therapies, including targeted therapies, immunotherapies, and emerging treatment modalities that are reshaping the landscape of hematologic malignancies.
  3. Biomarkers and Disease Monitoring:
    Research on biomarkers for diagnosis, prognosis, and monitoring of treatment responses, particularly in the context of measurable residual disease (MRD) and precision medicine, is a core focus.
  4. Patient-Centered Care and Quality of Life:
    The journal emphasizes the importance of patient-centered approaches, including the evaluation of quality of life and psychosocial factors in the management of hematologic malignancies.
  5. Multidisciplinary Approaches and Collaborative Care:
    It promotes a multidisciplinary perspective, highlighting the importance of collaboration among hematologists, oncologists, pathologists, and other healthcare professionals in the treatment of hematologic malignancies.
Recent publications in 'Current Hematologic Malignancy Reports' indicate several emerging themes and trends. These reflect the evolving research landscape and clinical priorities in the management of hematologic malignancies.
  1. Targeted and Bispecific Antibody Therapies:
    There is a growing focus on targeted therapies and bispecific antibodies, particularly in the treatment of multiple myeloma and other hematologic malignancies, highlighting advancements in precision medicine.
  2. Impact of Technology in Patient Management:
    Emerging themes related to the use of technology, such as digital interventions and telemedicine, are increasingly prominent, reflecting the adaptation of healthcare delivery to enhance patient engagement and care.
  3. Research on MRD and Disease Monitoring Techniques:
    The trend towards understanding measurable residual disease (MRD) and its implications for treatment decisions is gaining traction, emphasizing its critical role in the management of various hematologic malignancies.
  4. Patient Quality of Life and Financial Toxicity:
    There is an increased emphasis on the quality of life for patients and the financial implications of treatment, addressing the holistic aspects of patient care and the socioeconomic challenges faced by individuals with hematologic malignancies.
  5. Emerging Insights into Genetic and Molecular Pathogenesis:
    Recent publications highlight a trend towards understanding the genetic and molecular underpinnings of hematologic malignancies, paving the way for novel therapeutic targets and improved prognostic stratification.

Declining or Waning

While the journal has consistently focused on several core themes, certain areas appear to be declining in prominence as new trends emerge in the field of hematologic malignancies. This section highlights those waning themes.
  1. Traditional Chemotherapy Regimens:
    There is a noticeable reduction in articles focusing on traditional chemotherapy regimens, as the field shifts towards targeted therapies and personalized medicine, reflecting a broader trend in oncology.
  2. Conventional Diagnostic Techniques:
    The use of conventional diagnostic techniques is mentioned less frequently, as advancements in molecular profiling and next-generation sequencing are becoming the standard, indicating a transition towards more sophisticated diagnostic approaches.
  3. Generalized Treatment Protocols:
    There is a decline in the publication of generalized treatment protocols, with a growing focus on tailored treatment strategies that consider individual patient characteristics and disease biology.

Similar Journals

SEMINARS IN HEMATOLOGY

Advancing Hematology Through Insightful Research.
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 0037-1963Frequency: 4 issues/year

SEMINARS IN HEMATOLOGY, published by W B SAUNDERS CO-ELSEVIER INC, stands as a premier academic journal dedicated to the field of hematology. Established in 1964, this journal has built a robust reputation over its nearly six-decade history, now recognized as a Q1 journal in Hematology with an impressive impact factor reflective of its high relevance and citation frequency within the academic community. Residents and scholars can access meticulously curated articles that address innovative research, clinical practices, and advancements in the understanding of blood disorders and treatment methodologies. The journal, ranked #36 out of 137 in the Scopus Medicine Hematology category, showcases cutting-edge research, ensuring its contributions are crucial for professionals, researchers, and students striving to stay at the forefront of the hematology field. Although not an Open Access journal, SEMINARS IN HEMATOLOGY continues to unite a global audience dedicated to advancing the science and clinical practices in hematology.

Advances in Digestive Medicine

Connecting Research and Clinical Practice in Digestive Health
Publisher: WILEYISSN: 2351-9797Frequency: 4 issues/year

Advances in Digestive Medicine is a premier scholarly journal dedicated to the evolving field of gastrointestinal health and diseases. Published by WILEY, this journal aims to disseminate high-quality research encompassing a wide range of topics related to digestive medicine, from foundational studies to innovative clinical applications. As a significant resource for researchers, professionals, and students alike, Advances in Digestive Medicine fosters a deeper understanding of digestive disorders, promoting collaboration and knowledge exchange within the scientific community. Although it offers subscription-based access, the journal ensures comprehensive coverage of groundbreaking studies that significantly impact clinical practice and patient care in the field. With an ISSN of 2351-9797 and an E-ISSN of 2351-9800, it stands as an essential platform for anyone involved in digestive health research.

Therapeutic Advances in Medical Oncology

Catalyzing collaboration for improved cancer outcomes.
Publisher: SAGE PUBLICATIONS LTDISSN: 1758-8340Frequency: 1 issue/year

Therapeutic Advances in Medical Oncology, an esteemed journal published by SAGE Publications Ltd, serves as a critical platform for disseminating high-quality research pertinent to the field of oncology. Indexed under the ISSN 1758-8340 and E-ISSN 1758-8359, this Open Access journal has made significant strides since its inception in 2009, attaining a commendable rank of #78 out of 404 in the Medicine - Oncology category of Scopus, placing it in the top 20th percentile of journals. With its category quartile of Q1 established in 2023, it underscores the journal’s commitment to advancing therapeutic approaches in oncology, making it an invaluable resource for researchers, clinicians, and students alike. Offering unrestricted access to pioneering studies since 2017, it aligns with the global movement towards open science, fostering collaboration and innovation among professionals striving to improve cancer treatment outcomes. By bridging the gap between research and clinical practice, Therapeutic Advances in Medical Oncology plays a vital role in shaping the future of cancer therapy.

REVUE DES MALADIES RESPIRATOIRES

Exploring the frontiers of respiratory medicine.
Publisher: MASSON EDITEURISSN: 0761-8425Frequency: 10 issues/year

REVUE DES MALADIES RESPIRATOIRES is a distinguished journal published by MASSON EDITEUR, focusing on the vital field of pulmonary and respiratory medicine. Established in 1984, this journal has become a prominent platform for sharing innovative research and clinical findings, reflecting an impressive array of studies that contribute to our understanding of respiratory diseases. With its ISSN 0761-8425 and E-ISSN 1776-2588, it facilitates access to scholarly work within the medical community, although it currently operates under a subscription model rather than Open Access. As indicated by its quartile ranking of Q4 in 2023 within its category and a Scopus rank of #128/155, REVUE DES MALADIES RESPIRATOIRES serves as an essential resource for researchers, professionals, and students aiming to stay informed about advancements in respiratory health. This journal plays a crucial role in fostering discussions that drive innovation and best practices in the treatment and understanding of respiratory conditions.

Case Reports in Oncological Medicine

Empowering healthcare professionals with valuable case reports.
Publisher: HINDAWI LTDISSN: 2090-6706Frequency: 1 issue/year

Case Reports in Oncological Medicine is a distinguished open-access journal published by HINDAWI LTD, dedicated to disseminating valuable insights and findings in the field of oncology. Since its inception in 2011, this journal has aimed to provide a unique platform for the publication of detailed case reports that contribute to our understanding of cancer diagnosis, treatment, and management. With a specific focus on sharing clinical experiences and outcomes, it seeks to engage researchers, healthcare professionals, and students who are committed to advancing oncological knowledge and improving patient care. Although coverage in Scopus was discontinued from 2014 to 2017, the journal currently holds a rank of #232/323 in Medicine - Oncology, placing it within the 28th percentile. Researchers interested in making their work accessible can benefit from the journal's open-access model, allowing greater visibility and citation potential within the scientific community. The journal is positioned as an important resource for those looking to stay updated on the latest case studies and innovations in oncological medicine.

CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Advancing kidney health and blood pressure insights.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1062-4821Frequency: 6 issues/year

CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION is a premier academic journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and research in the fields of nephrology and hypertension. Since its inception in 1992, this journal has been an essential resource for professionals seeking to stay at the forefront of kidney health and blood pressure management. With a distinguished ranking in the top quartile (Q1) for both Internal Medicine and Nephrology as of 2023, the journal is recognized for its high impact, currently holding a Scopus rank of #16 out of 81 in Nephrology, positioning it in the 80th percentile. Although not an open access journal, it provides crucial insights and expert opinions that cater to researchers, clinicians, and students committed to improving patient outcomes through evidence-based practice. The journal continues to emphasize its objectives of disseminating pivotal findings and fostering discussions that bridge the gap between clinical practice and research, making it an invaluable asset in the evolving landscape of nephrology and hypertension.

Current Problems in Cancer: Case Reports

Transforming patient care through diverse oncology perspectives.
Publisher: ELSEVIERISSN: 2666-6219Frequency: 2 issues/year

Current Problems in Cancer: Case Reports is a prominent scholarly journal published by Elsevier, focusing on critical case reports within the field of oncology. Since its transition to Open Access in 2020, it has enhanced accessibility for researchers and healthcare professionals seeking to share and discuss unique clinical scenarios and insights that advance cancer treatment and patient care. Operating from the United States, this journal aims to address the important and often intricate challenges faced in oncology, facilitating a platform for knowledge exchange and the exploration of new perspectives in cancer management. Despite its current Q4 category ranking in the 2023 oncology category of Scopus with a rank of #359/404, its goal is to enrich the academic discourse by featuring diverse case reports and promoting evidence-based practices. As the journal evolves from 2021 to 2024, it seeks to impact the field by inviting researchers, professionals, and students to contribute their findings, ultimately fostering a collaborative environment for tackling the complexities of cancer.

BLOOD

Illuminating Innovations in Hematology and Immunology.
Publisher: AMER SOC HEMATOLOGYISSN: 0006-4971Frequency: 52 issues/year

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.

Precision Medical Sciences

Innovating research in precision medicine for global impact.
Publisher: WILEYISSN: 2642-2514Frequency: 4 issues/year

Precision Medical Sciences is a pioneering open-access journal, launched in 2020 and published by the esteemed WILEY, dedicated to disseminating cutting-edge research and advancements in the field of precision medicine. With the ISSN 2642-2514, this journal serves as a critical platform for researchers, healthcare professionals, and students to explore innovative approaches that personalize medical treatment, optimize patient outcomes, and advance the understanding of patient variability in response to therapies. The adoption of open-access policies ensures that groundbreaking findings are readily available to the global scientific community, fostering collaboration and knowledge sharing among experts. Although currently lacking an H-index, the journal aspires to establish a robust reputation in the medical literature landscape, supporting the ongoing evolution of tailored healthcare solutions. Researchers are encouraged to contribute their findings to enhance the journal’s commitment to excellence in precision medical sciences.

Nature Reviews Clinical Oncology

Connecting Knowledge and Innovation in Oncology
Publisher: NATURE PORTFOLIOISSN: 1759-4774Frequency: 12 issues/year

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.